StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a report issued on Saturday. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
RDHL opened at $5.77 on Friday. The firm has a 50 day moving average price of $6.69 and a 200 day moving average price of $46.03. RedHill Biopharma has a 1 year low of $5.41 and a 1 year high of $20.27.
Institutional Investors Weigh In On RedHill Biopharma
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC purchased a new position in RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Featured Stories
- Five stocks we like better than RedHill Biopharma
- Transportation Stocks Investing
- How to Invest in Small Cap Stocks
- 3 Warren Buffett Stocks to Buy Now
- These Are the Dividend Stocks Insiders Bought in January
- Short Selling – The Pros and Cons
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.